Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy

Immunoregulatory functions of VISTA

(2017) Elizabeth C. Nowak et al.   IMMUNOLOGICAL REVIEWS

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

(2017) Tomasz M. Beer et al.   JOURNAL OF CLINICAL ONCOLOGY

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

(2017) Jianjun Gao et al.   NATURE MEDICINE

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

(2016) Julie N. Graff et al.   Oncotarget

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

(2014) Lawrence Fong et al.   JNCI-Journal of the National Cancer Institute

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE